CN106110055A - 一种松苓草颗粒及其制备方法 - Google Patents
一种松苓草颗粒及其制备方法 Download PDFInfo
- Publication number
- CN106110055A CN106110055A CN201610563078.3A CN201610563078A CN106110055A CN 106110055 A CN106110055 A CN 106110055A CN 201610563078 A CN201610563078 A CN 201610563078A CN 106110055 A CN106110055 A CN 106110055A
- Authority
- CN
- China
- Prior art keywords
- extract
- time
- preparation
- filtrate
- extracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 82
- 244000025254 Cannabis sativa Species 0.000 title claims abstract description 26
- 241001251949 Xanthium sibiricum Species 0.000 title claims abstract description 26
- 239000002245 particle Substances 0.000 title claims abstract description 24
- 235000008331 Pinus X rigitaeda Nutrition 0.000 title claims abstract description 20
- 235000011613 Pinus brutia Nutrition 0.000 title claims abstract description 20
- 241000018646 Pinus brutia Species 0.000 title claims abstract description 20
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 329
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 114
- 239000000706 filtrate Substances 0.000 claims description 101
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 83
- 210000000582 semen Anatomy 0.000 claims description 55
- 238000010438 heat treatment Methods 0.000 claims description 50
- 238000000605 extraction Methods 0.000 claims description 47
- 238000010992 reflux Methods 0.000 claims description 30
- 241000218628 Ginkgo Species 0.000 claims description 26
- 235000011201 Ginkgo Nutrition 0.000 claims description 26
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 26
- 241000005787 Cistanche Species 0.000 claims description 23
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 23
- 241000190633 Cordyceps Species 0.000 claims description 22
- 241000628997 Flos Species 0.000 claims description 20
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 14
- 235000020710 ginseng extract Nutrition 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 9
- 241000208340 Araliaceae Species 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000002137 ultrasound extraction Methods 0.000 claims description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 7
- 235000008434 ginseng Nutrition 0.000 claims description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- -1 1- 3h Substances 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 239000001630 malic acid Substances 0.000 claims description 6
- 235000011090 malic acid Nutrition 0.000 claims description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 6
- 239000000811 xylitol Substances 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 6
- 229960002675 xylitol Drugs 0.000 claims description 6
- 235000010447 xylitol Nutrition 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 244000294611 Punica granatum Species 0.000 claims description 5
- 235000014360 Punica granatum Nutrition 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 108010059892 Cellulase Proteins 0.000 claims description 4
- 240000002853 Nelumbo nucifera Species 0.000 claims description 4
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 4
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 4
- 210000002421 cell wall Anatomy 0.000 claims description 4
- 229940106157 cellulase Drugs 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 30
- 239000008280 blood Substances 0.000 abstract description 30
- 206010020772 Hypertension Diseases 0.000 abstract description 10
- 206010003246 arthritis Diseases 0.000 abstract description 10
- 230000002503 metabolic effect Effects 0.000 abstract description 10
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000001421 hyperglycemia Diseases 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 22
- 210000000952 spleen Anatomy 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000756042 Polygonatum Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- TUODPMGCCJSJRH-KWQFWETISA-N (2s,3r)-2,3-dihydroxy-2-[(4-hydroxyphenyl)methyl]butanedioic acid Chemical compound OC(=O)[C@H](O)[C@](O)(C(O)=O)CC1=CC=C(O)C=C1 TUODPMGCCJSJRH-KWQFWETISA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 235000011609 Pinus massoniana Nutrition 0.000 description 1
- 241000018650 Pinus massoniana Species 0.000 description 1
- 235000011610 Pinus tabuliformis Nutrition 0.000 description 1
- 241000018651 Pinus tabuliformis Species 0.000 description 1
- 241001448326 Polygonatum cirrhifolium Species 0.000 description 1
- 241001468611 Polygonatum cyrtonema Species 0.000 description 1
- 241000037826 Polygonatum kingianum Species 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- TUODPMGCCJSJRH-UHFFFAOYSA-N piscidic acid Natural products OC(=O)C(O)C(O)(C(O)=O)CC1=CC=C(O)C=C1 TUODPMGCCJSJRH-UHFFFAOYSA-N 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种松苓草颗粒及其制备方法,用于治疗高脂血症,降低血脂、高血糖和高尿酸症,与现有技术相比,本发明中各原料之间相互协同,配合使用,制得的口服液不仅可以降低血脂、血糖,同时治疗缓解高血脂、高血压高血糖、高尿酸带来的并发症,提高治疗效果,提高服用者的免疫力和健康水平,治疗见效快、效果好。
Description
技术领域
本发明属于医药领域,具体涉及一种松苓草颗粒及其制备方法。
背景技术
血脂过高称为高脂血症,是指各种原因导致的血浆中胆固醇和/或甘油三酯水平升高。血浆中的脂质除胆固醇和甘油三脂外,还包括磷脂、糖脂、固醇和类固醇,广泛存在于人体各组织中,它们是细胞的基础代谢必需物质。
血脂的来源有两部分:外源和内源。外源是指食物中的脂类经消化吸收入血的,后者是体内合成组织动员出来的脂类。血脂的去路是不断被组织摄取或作为能源储存,或作为燃料氧化供能或构成生物膜及其他物质。
高脂血症的直接损害是加速全身动脉粥样硬化,因为全身的重要器官都要依靠动脉供血、供氧,一旦动脉被粥样斑块堵塞,就会导致一系列严重后果。动脉粥样硬化引起的肾功能衰竭等都与高脂血症密切相关。大量研究资料表明,高脂血症是脑中风、冠心病、心肌梗死等疾病的重要危险因素。
此外,高脂血症也是促进高血压、糖耐量异常、糖尿病的一个重要危险因素。高脂血症还可导致脂肪肝、肝硬化、胆石症、胰腺炎、眼底出血乃至失明、周围血管病变、高尿酸血症。高尿酸症与高血压存在着紧密的联系,研究表示,尿酸可致高血压发生;高血压并合并高尿酸症的患者容易发生冠心病、死亡率升高。
发明内容
本发明的目的在于提供一种松苓草颗粒及其制备方法,用于治疗高脂血症,降低血脂、降血压、降血糖,治疗高尿酸症。
本发明提供的一种松苓草颗粒,含有以下重量份的原料:
所述人参膏的制备方法为:
将购买的人参研磨成粉,加入6-7倍重量的体积分数80%的乙醇加热回流提取3-4次,每次0.8-1.5h;合并滤液,减压干燥,制得人参膏。
所述茯苓提取物的制备方法为:
将茯苓烘干粉碎后,过40-60目筛,加入50-60倍量的水,超声提取25-30min;过滤,得滤液,减压浓缩干燥,制得茯苓提取物。
所述虫草提取物的制备方法为:
将虫草粉碎,加热提取3次,第一次加5-7倍重量的水在65-70℃下提取1.5-2h;第二次加4-6倍量水,68-70℃下提取0.5-1.5h,第3次加3-5倍量水,65-70℃提取0.5-1.5h,每次滤过,合并滤液,滤液减压浓缩,干燥,得到虫草提取物。
所述松花粉提取物的制备方法为:
准确称取松花粉加热回流提取2次,第一次加入15-20重量倍的水,回流提取1-2h;第二次加入10-12倍重量的水,回流提取1-2h,每次滤过,合并滤液,浓缩冷冻干燥,得松花粉提取物。
所述黄精提取物的制备方法为:
将黄精粉碎,过20-40目筛,用石油醚80-90℃回流脱脂后,加热提取3次,第一次加10-18倍重量的水在90-95℃下提取1.5-2h;第二次加10-15倍量水在85-90℃提取0.5-1.5h,第3次加8-12倍量水在85-90℃提取0.5-1.5h,每次滤过,合并滤液,滤液减压浓缩,干燥,得到黄精提取物。
所述肉苁蓉提取物的制备方法为:
将肉苁蓉粉碎,加热提取3次,第一次加10-12倍重量的水在80-85℃下提取1.5-2h;第二次加8-10倍量水在85-90℃提取0.5-1.5h,第3次加6-8倍量水在85-90℃提取0.5-1h,每次滤过,合并滤液,滤液减压浓缩,干燥,得到肉苁蓉提取物。
所述山楂叶提取物的制备方法:
称取山楂叶,加入15-20倍量的蒸馏水、0.2-0.4%的纤维素酶和0.2-0.4%的果胶酶,用盐酸调pH值到4-5,在45-55℃恒温振荡酶解100-150min,先对山楂叶细胞壁进行破坏,然后升温到85-90℃下浸提60-90min;待冷却至室温后,离心分离,得上清液;剩余山楂叶残渣用80-90℃水洗涤1次,离心分离,得洗涤液;将2次上清液合并,滤液减压浓缩,干燥,得到山楂叶提取物。
所述冬瓜皮提取物的制备方法为:
将冬瓜皮用8-10倍乙醇回流提取3-4次,每次提取1-2h;残渣挥发去掉乙醇后,加入残渣8-10倍重量的水提取2-3次,每次提取1-2h;过滤后,滤液减压浓缩,干燥,即得冬瓜皮提取物。
所述银杏提取物的制备方法为:
将干银杏粉碎过40-60目筛,用乙醇超声提取2次,第一次加入10-20倍的体积分数90%的乙醇,在70℃下400W功率下提取1-2h;第二次在10-15倍的体积分数75%的乙醇,在60-70℃下300W功率下提取1-2h,合并滤液,减压浓缩、干燥,得到银杏提取物。
所述月见草提取物的制备方法为:
月见草粉碎过40-60目筛,用25-30倍重量的体积分数80%的乙醇加热80-90℃,回流提取2次,每次合并滤液,浓缩后,再加入3-4倍体积量的体积分数95%的乙醇除杂,离心后,得滤液,滤液浓缩得月见草提取物。
所述大黄提取物的制备方法为:
将大黄粉碎,加热提取2次,第一次加8-11倍量水在70-90℃提取0.5-2h,第二次加6-8倍量水在85-95℃提取0.5-1h,每次滤过,合并滤液,滤液减压浓缩,干燥,得到大黄提取物。
所述荷叶提取物的制备方法为:
将荷叶烘干、粉碎,过100-160目筛,加入体积浓度60%的乙醇,浸泡10-12h,浸泡后的荷叶粉末用40-45倍重量的体积浓度75%的乙醇超声提取20-25min,滤液浓缩干燥,得到荷叶提取物。
所述车前子提取物的制备方法为:
将车前子粉碎,加热提取3次,第一次加25-30重量倍的水在80-95℃下提取1.5-2h;第二次加15-25倍量水,80-90℃下提取0.5-1.5h,第3次加25-28倍量水,80-90℃提取0.5-2h,每次滤过,合并滤液,滤液减压浓缩,干燥,得到车前子提取物。
所述菊花提取物的制备方法为:
称取菊花适量,回流提取两次,第一次加6-15倍量水,浸泡超声0.5-1h,提取0.5-2h,过滤,第二次加6-15倍量水,提取0.5-2h,过滤,两次滤液合并,滤液减压浓缩,干燥,即得菊花提取物。
所述番石榴叶提取物的制备方法为:
称取番石榴叶适量,加热提取两次,第一次加5-10倍量水,加热煎煮至80-90℃,提取0.5-2h,过滤,第二次加6-8倍量水,加热至85-90℃,提取0.5-2h,过滤,两次滤液合并,滤液减压浓缩,干燥,即得石榴叶提取物。
所述薏苡仁提取物的制备方法为:
称取薏苡仁适量,粉碎,加热提取两次,第一次加5-7倍量水,加热煎煮至70-90℃,提取0.5-2h,过滤,第二次加6-8倍量水,加热至85-90℃,提取1-2h,过滤,两次滤液合并,滤液减压浓缩,干燥,即得薏苡仁提取物。
所述当归提取物的制备方法为:
当归粉碎后,于12-15倍重量的体积分数70%的乙醇溶液中浸泡10-12h后,回流提取1-3h,滤液减压浓缩,干燥,即得当归提取物。
所述葛根提取物的制备方法为:
将葛根粉碎,加热提取3次,第一次加25-30重量倍的水在80-95℃下提取1.5-2h;第二次加15-25倍量水,80-90℃下提取0.5-1.5h,第3次加25-28倍量水,80-90℃提取0.5-2h,每次滤过,合并滤液,减压浓缩,干燥,得到葛根提取物。
本发明提供的一种松苓草颗粒的制备方法,包括以下步骤:
(1)将配方中的人参膏、茯苓提取物、虫草提取物、松花粉提取物、黄精提取物、肉苁蓉提取物、山楂叶提取物、冬瓜皮提取物、银杏叶提取物、月见草提取物、大黄提取物、荷叶提取物、车前子提取物、菊花提取物、番石榴叶提取物、薏苡仁提取物、当归提取物和葛根提取物搅拌混匀;
(2)加入配方量的苹果酸、CMC和木糖醇,搅拌混匀,制颗粒,干燥,即得松苓草颗粒。
本发明中各原料的作用为:
人参为五加科植物人参的干燥根。具有大补元气复脉固脱、补脾益肺、生津、安神之功效。用于体虚欲脱、肢冷脉微、脾虚食少、肺虚喘咳、津伤口渴、内热消渴、久病虚赢、惊悸失眠、阳痿宫冷、心力衰竭、心源性休克等。人参皂苷大多具有增加白细胞数量、提高人体免疫力、促进物质代谢、抗疲劳、抗衰老等作用。提取工艺的设计通过将活性成分和药效相结合的方法使中药提取产物,与银杏、肉苁蓉等配伍,突出其在治疗高血脂方面的疗效。
茯苓具有凝神、健脾、利水渗湿等作用,能够调节免疫系统功能、抗肿瘤、延缓衰老、防治结石、促进尿酸排泄等作用。利用超声辅助法提取茯苓有效成分,控制料液比和多糖粉碎的目数,提高提取效率,在获得较高含量活性成分的基础上保证药效最好。
虫草中含有虫草素、虫草酸、虫草多糖、SOD和氨基酸等多种生物活性物质,对于肾衰、癌症、肺气肿和糖尿病等有积极的医疗作用。虫草多糖是一种高度分枝的半乳甘露聚糖,它能促使淋巴细胞转化,提高血清lgG的抗体含量和机体的免疫功能,增强机体自身抗癌的能力,提高肝脏解毒功能,起到护肝作用。
黄精为百合科植物多花黄精、滇黄精、卷叶黄精等的干燥根茎,别名鸡头黄精、鸡头根。其具有补中益气、滋润心肺、强壮筋骨等作用,久服可以延年益寿,为“药食同源”植物。黄精多糖是黄精水提物的主要有效成分,也是黄精主要生物活性成分。现代药理证实,黄精多糖具有降血糖、降血脂、增强免疫功能、抗衰老等多种功能。大量的药理和临床研究表明,一些多糖类化合物具有免疫调节作用,能够激活机体的免疫细胞,提高其免疫功能。
松花粉是马尾松、油松或同属数种植物的雄性生殖细胞,经人工收集,除杂,干燥所得的黄色粉末,是中华医药学宝库中药、食兼用的花粉品种之一。松花粉不仅含有丰富的营养成分,如花粉多糖、蛋白质、纤维素、不饱和脂肪酸、微量元素,还含有多酚类化合物、核酸和植物甾醇等生物活性成分,具有很高的保健价值。研究表明,花粉具有抗癌、抗疲劳、抗炎症、抗衰老、提高机体免疫功能,并能降低血清胆固醇,抗动脉粥样硬化,对化学物质致肝肾损伤也有明显保护作用。
肉苁蓉主要可分为苯乙醇苷类、环烯醚萜类、木脂素类、多糖、十几种氨基酸、多种生物碱等,富含人体所需微量元素;具有提高免疫力、抗衰老、保护肝脏和心脑血管的功效。本发明设计水提取肉苁蓉,主要获得肉苁蓉中甜菜碱有效成分,对降血脂、保护心脑血管具有显著疗效。
山楂叶中总黄酮含量较高,具有降血脂、降血压的效果。本发明利用山楂叶酶解提取山楂黄酮,提取效率高,药效好。
冬瓜皮含有蜡类、树脂类、挥发性物质、三萜类化合物、胆甾醇衍生物、有机酸、烟酸、胡萝卜素、多糖等成分冬瓜皮药用历史悠久,该药可入复方或水单煎治疗消渴症,祖国传统医学认为冬瓜皮味甘、性寒,归脾、小肠经,有清热止渴、利水消肿、解毒生津之功效。冬瓜皮具有无脂、低钠等特点,可去除体内多余的脂肪,特别适合糖尿病人食用。多年研究表明,冬瓜皮中的多糖类成分可显著降低血糖水平且无明显毒副作用。
银杏,《本草纲目》记载其性甘、苦、涩,归心经、肺经,功能敛肺、平喘、活血化瘀、止痛,可用于治疗肺虚咳喘、冠心病、心绞痛、高血脂等。银杏叶中黄酮类物质,具有活血化瘀作用,临床上主要用于动脉硬化及高血压所致的冠状动脉供血不全、心绞痛、心肌梗塞、脑栓塞、脑血管痉挛等心脑血管疾病的治疗。
月见草植物体含黄酮类、三萜酸等多种化学成分,其中叶中黄酮含量高,具有抗肿瘤、抗氧化、降血脂等生理功能,是一种优质天然的保健食品资源。本发明乙醇加热回流提取,提取效率高。
大黄、苦,寒;归脾、胃、大肠、肝、心包经;泻下攻积,清热泻火,凉血解毒,逐瘀通经,利湿退黄;还具有降低胆固醇、降血压的作用。
荷叶中除了含有碳水化合物、脂质、蛋白质等常规成分外,还富含多种生物碱、黄酮类化合物,具有抑菌、降脂、减肥,清除人体有害自由基,抗衰老、美容、止痉孪保健、治疗心血管疾病等功能。本发明中先将荷叶粉碎至粒径较小的粉末,然后用乙醇浸泡后在超声提取,获得的提取物中有效成分含量高,而且药效显著。
车前子,性味甘寒,入肾、膀胱、肝、肺经,功能利水通淋、渗湿止泻、清肝明目、清热化痰,为常用药材。本发明中,车前子与冬瓜、大黄、银杏和黄精等配伍使用,具有降低血脂、清热利尿的作用,能够降尿酸。
番石榴叶味苦;涩;性平,叶含β-谷甾醇、三萜类。又含槲皮素,番石榴鞣花甙,无色矢车菊素,番大榴鞣花甙,番石榴酸,扁蓄甙(一说不含有);并含挥发油,对高血糖疗效显著,高血糖、高血压和高血脂是相互关联的,三种病症往往同时或者相继出现,在本发明在组合物中加入番石榴叶、月见草,与其他原料配伍使用,缓解三高患者的病痛。
薏苡仁甘、淡,凉;归脾、胃、肺经。有利水渗湿,健脾止泻,除痹,排脓,解毒散结的功效。与车前子、茯苓、大黄配伍,具有健脾化浊,促进尿酸排泄的作用。
菊花清热解毒,与荷叶、黄精、银杏等配伍使用,具有降低血压和血脂的作用。
当归具有补血和血,调经止痛,润燥滑肠、抗癌、抗老防老、免疫之功效;在本发明中与大黄配伍,抑制尿酸合成、改善肾血液流量。
葛根,甘、辛,凉。有解肌退热,透疹,生津止渴,升阳止泻之功。常用于表证发热,项背强痛,麻疹不透,热病口渴,阴虚消渴,热泻热痢,脾虚泄泻。本发明中,葛根与川穹、银杏和黄精等配伍使用,具有降低血脂、降血压的作用。
本发明中加入人参、茯苓和虫草有效成分提取物,与黄精、肉苁蓉、山楂叶、冬瓜、葛根、银杏等配伍使用,协同作用,保证降低血脂、血压的疗效基础上,提高服用者的免疫力、抵抗力,健脾益肺。本发明中加入山楂叶、荷叶提取物,不仅具有协同发挥降血脂的作用,而且,调节口服液的味道,中和其他中药的味道,使口服液口感更好。本发明中茯苓、大黄、车前子、当归、薏苡仁的加入,可以治疗高血脂带来的并发症,降低胆固醇,促进尿酸排泄、抑制尿酸形成,治疗高尿酸症,提高治疗效果。
与现有技术相比,本发明中各原料之间相互协同,配合使用,制得的口服液不仅可以降低血脂、血糖,同时治疗缓解高血脂、高血压高血糖、高尿酸带来的并发症,提高治疗效果,提高服用者的免疫力和健康水平,治疗见效快、效果好。
具体实施方式
实施例1
一种松苓草颗粒,含有以下重量份的原料:
人参膏2份
茯苓提取物10份
虫草提取物10份
松花粉提取物6份
黄精提取物9份
肉苁蓉提取物7份
山楂叶提取物7份
冬瓜皮提取物3份
银杏叶提取物3份
月见草提取物3份
大黄提取物4份
荷叶提取物4份
车前子提取物3份
菊花提取物3份
番石榴叶提取物2份
薏苡仁提取物2份
当归提取物3份
葛根提取物3份
苹果酸0.03份
CMC0.02份
木糖醇95份。
所述人参膏的制备方法为:
将购买的人参研磨成粉,加入7倍重量的体积分数80%的乙醇加热回流提取3次,每次0.8-1.5h;合并滤液,减压干燥,制得人参膏。
所述茯苓提取物的制备方法为:
将茯苓烘干粉碎后,过40目筛,加入50倍量的水,超声提取30min;过滤,得滤液,减压浓缩干燥,得茯苓提取物。
所述虫草提取物的制备方法为:
将虫草粉碎,加热提取3次,第一次加5倍重量的水在65℃下提取2h;第二次加5倍量水,68℃下提取1h,第3次加4倍量水,70℃提取1.5h,每次滤过,合并滤液,减压浓缩干燥,得到虫草提取物。
所述松花粉提取物的制备方法为:
准确称取松花粉加热回流提取2次,第一次加入16重量倍的水,回流提取1.5h;第二次加入11倍重量的水,回流提取2h,每次滤过,合并滤液,浓缩冷冻干燥,得松花粉提取物。
所述黄精提取物的制备方法为:
将黄精粉碎,过20目筛,用石油醚90℃回流脱脂后,加热提取3次,第一次加12倍重量的水在95℃下提取1.5h;第二次加10倍量水在90℃提取1.5h,第3次加10倍量水在85℃提取1.5h,每次滤过,合并滤液,减压浓缩干燥,得到黄精提取物。
所述肉苁蓉提取物的制备方法为:
将肉苁蓉粉碎,加热提取3次,第一次加10倍重量的水在80-85℃下提取2h;第二次加9倍量水在90℃提取1h,第3次加7倍量水在85℃提取1h,每次滤过,合并滤液,减压浓缩干燥,得到肉苁蓉提取物。
所述山楂叶提取物的制备方法:
称取山楂叶,加入15倍量的蒸馏水、0.4%的纤维素酶和0.2%的果胶酶,用盐酸调pH值到4,在45℃恒温振荡酶解100min,先对山楂叶细胞壁进行破坏,然后升温到85℃下浸提70min;待冷却至室温后,离心分离,得上清液;剩余山楂叶残渣用80℃水洗涤1次,离心分离,得洗涤液;将2次上清液合并,减压浓缩干燥,得到山楂叶提取物。
所述冬瓜皮提取物的制备方法为:
将冬瓜皮用9倍乙醇回流提取3次,每次提取1h;残渣挥发去掉乙醇后,加入残渣9倍重量的水提取2次,每次提取1h;过滤后,滤液减压浓缩干燥,即得冬瓜皮提取物。
所述银杏提取物的制备方法为:
将干银杏粉碎过50目筛,用乙醇超声提取2次,第一次加入10倍的体积分数90%的乙醇,在70℃下400W功率下提取1-2h;第二次在12倍的体积分数75%的乙醇,在70℃下300W功率下提取1h,合并滤液,减压浓缩,得到银杏提取物。
所述月见草提取物的制备方法为:
月见草粉碎过60目筛,用30倍重量的体积分数80%的乙醇加热90℃,回流提取2次,每次合并滤液,浓缩后,再加入3倍体积量的体积分数95%的乙醇除杂,离心后,得滤液,滤液浓缩得,月见草提取物。
所述大黄提取物的制备方法为:
将大黄粉碎,加热提取2次,第一次加8倍量水在70℃提取1h,第二次加7倍量水在90℃提取0.5h,每次滤过,合并滤液,减压浓缩干燥,得到大黄提取物。
所述荷叶提取物的制备方法为:
将荷叶烘干、粉碎,过120目筛,加入体积浓度60%的乙醇,浸泡12h,浸泡后的荷叶粉末用45倍重量的体积浓度75%的乙醇超声提取20min,滤液浓缩干燥,得到荷叶提取物。
所述车前子提取物的制备方法为:
将车前子粉碎,加热提取3次,第一次加25重量倍的水在95℃下提取1.5h;第二次加15倍量水,80℃下提取1h,第3次加26倍量水,80℃提取1h,每次滤过,合并滤液,减压浓缩干燥,得到车前子提取物。
所述菊花提取物的制备方法为:
称取菊花适量,回流提取两次,第一次加8倍量水,浸泡超声1h,提取1h,过滤,第二次加10倍量水,提取1h,过滤,两次滤液合并,减压浓缩干燥,即得菊花提取物。
所述番石榴叶提取物的制备方法为:
称取番石榴叶适量,加热提取两次,第一次加6倍量水,加热煎煮至90℃,提取0.5-12h,过滤,第二次加7倍量水,加热至90℃,提取2h,过滤,两次滤液合并,滤液减压浓缩,干燥,即得石榴叶提取物。
所述薏苡仁提取物的制备方法为:
称取薏苡仁适量,粉碎,加热提取两次,第一次加5倍量水,加热煎煮至80℃,提取1.5h,过滤,第二次加8倍量水,加热至85-90℃,提取1.5h,过滤,两次滤液合并,滤液减压浓缩,干燥,即得薏苡仁提取物。
所述当归提取物的制备方法为:
当归粉碎后,于14倍重量的体积分数70%的乙醇溶液中浸泡12h后,回流提取2h,滤液减压浓缩,干燥,即得当归提取物。
所述葛根提取物的制备方法为:
将葛根粉碎,加热提取3次,第一次加27重量倍的水在80-95℃下提取2h;第二次加20倍量水,85℃下提取1.5h,第3次加28倍量水,85℃提取1h,每次滤过,合并滤液,减压浓缩,干燥,得到葛根提取物。
本发明提供的一种松苓草颗粒的制备方法,包括以下步骤:
(1)将配方中的人参膏、茯苓提取物、虫草提取物、松花粉提取物、黄精提取物、肉苁蓉提取物、山楂叶提取物、冬瓜皮提取物、银杏叶提取物、月见草提取物、大黄提取物、荷叶提取物、车前子提取物、菊花提取物、番石榴叶提取物、薏苡仁提取物、当归提取物和葛根提取物搅拌混匀;
(2)加入配方量的苹果酸、CMC和木糖醇,搅拌混匀,制颗粒,干燥,即得松苓草颗粒。
实施例2
一种松苓草颗粒,含有以下重量份的原料:
人参膏3份
茯苓提取物8份
虫草提取物8份
松花粉提取物7份
黄精提取物9份
肉苁蓉提取物8份
山楂叶提取物8份
冬瓜皮提取物7份
银杏叶提取物4份
月见草提取物4份
大黄提取物5份
荷叶提取物3份
车前子提取物5份
菊花提取物5份
番石榴叶提取物2份
薏苡仁提取物4份
当归提取物3份
葛根提取物3份
苹果酸0.1份
CMC0.02份
木糖醇110份。
所述人参膏的制备方法为:
将购买的人参研磨成粉,加入7倍重量的体积分数80%的乙醇加热回流提取4次,每次1h;合并滤液,减压干燥,制得人参膏。
所述茯苓提取物的制备方法为:
将茯苓烘干粉碎后,过50目筛,加入60倍量的水,超声提取30min;过滤,得滤液,减压浓缩干燥,得茯苓提取物。
所述虫草提取物的制备方法为:
将虫草粉碎,加热提取3次,第一次加7倍重量的水在68℃下提取2h;第二次加5倍量水,70℃下提取1h,第3次加4倍量水,70℃提取1.5h,每次滤过,合并滤液,滤液减压浓缩干燥,得到虫草提取物。
所述松花粉提取物的制备方法为:
准确称取松花粉加热回流提取2次,第一次加入15重量倍的水,回流提取2h;第二次加入12倍重量的水,回流提取1h,每次滤过,合并滤液,浓缩冷冻干燥,得松花粉提取物。
所述黄精提取物的制备方法为:
将黄精粉碎,过30目筛,用石油醚90℃回流脱脂后,加热提取3次,第一次加15倍重量的水在95℃下提取2h;第二次加15倍量水在90℃提取1.5h,第3次加10倍量水在90℃提取1.5h,每次滤过,合并滤液,滤液减压浓缩干燥,得到黄精提取物。
所述肉苁蓉提取物的制备方法为:
将肉苁蓉粉碎,加热提取3次,第一次加12倍重量的水在85℃下提取1.5h;第二次加9倍量水在90℃提取1.5h,第3次加8倍量水在90℃提取1h,每次滤过,合并滤液,滤液减压浓缩干燥,得到肉苁蓉提取物。
所述山楂叶提取物的制备方法:
称取山楂叶,加入20倍量的蒸馏水、0.3%的纤维素酶和0.3%的果胶酶,用盐酸调pH值到4,在55℃恒温振荡酶解150min,先对山楂叶细胞壁进行破坏,然后升温到90℃下浸提80min;待冷却至室温后,离心分离,得上清液;剩余山楂叶残渣用90℃水洗涤1次,离心分离,得洗涤液;将2次上清液合并,减压浓缩干燥,得到山楂叶提取物。
所述冬瓜皮提取物的制备方法为:
将冬瓜皮用10倍乙醇回流提取4次,每次提取2h;残渣挥发去掉乙醇后,加入残渣10倍重量的水提取3次,每次提取2h;过滤后,滤液减压浓缩干燥,即得冬瓜皮提取物。
所述银杏提取物的制备方法为:
将干银杏粉碎过60目筛,用乙醇超声提取2次,第一次加入20倍的体积分数90%的乙醇,在70℃下400W功率下提取1.5h;第二次在15倍的体积分数75%的乙醇,在70℃下300W功率下提取2h,合并滤液,碱液浓缩,得到银杏提取物。
所述月见草提取物的制备方法为:
月见草粉碎过60目筛,用30倍重量的体积分数80%的乙醇加热90℃,回流提取2次,每次合并滤液,浓缩后,再加入4倍体积量的体积分数95%的乙醇除杂,离心后,得滤液,滤液减压浓缩干燥,得月见草提取物。
所述大黄提取物的制备方法为:
将大黄粉碎,加热提取2次,第一次加10倍量水在85℃提取1.5h,第二次加7倍量水在95℃提取1h,每次滤过,合并滤液,滤液减压浓缩干燥,得到大黄提取物。
所述荷叶提取物的制备方法为:
将荷叶烘干、粉碎,过60目筛,加入体积浓度60%的乙醇,浸泡12h,浸泡后的荷叶粉末用45倍重量的体积浓度75%的乙醇超声提取25min,滤液浓缩干燥,得到荷叶提取物。
所述车前子提取物的制备方法为:
将车前子粉碎,加热提取3次,第一次加30重量倍的水在80-95℃下提取2h;第二次加20倍量水,90℃下提取1.5h,第3次加28倍量水,90℃提取2h,每次滤过,合并滤液,滤液减压浓缩干燥,得到车前子提取物。
所述菊花提取物的制备方法为:
称取菊花适量,回流提取两次,第一次加15倍量水,浸泡超声1h,提取1h,过滤,第二次加10倍量水,提取1h,过滤,两次滤液合并,滤液减压浓缩干燥,即得菊花提取物。
所述番石榴叶提取物的制备方法为:
称取番石榴叶适量,加热提取两次,第一次加10倍量水,加热煎煮至90℃,提取2h,过滤,第二次加8倍量水,加热至90℃,提取1h,过滤,两次滤液合并,滤液减压浓缩,干燥,即得石榴叶提取物。
所述薏苡仁提取物的制备方法为:
称取薏苡仁适量,粉碎,加热提取两次,第一次加6倍量水,加热煎煮至90℃,提取1h,过滤,第二次加7倍量水,加热至90℃,提取2h,过滤,两次滤液合并,滤液减压浓缩,干燥,即得薏苡仁提取物。
所述当归提取物的制备方法为:
当归粉碎后,于14倍重量的体积分数70%的乙醇溶液中浸泡12h后,回流提取2h,滤液减压浓缩,干燥,即得当归提取物。
所述葛根提取物的制备方法为:
将葛根粉碎,加热提取3次,第一次加30重量倍的水在95℃下提取2h;第二次加15倍量水,90℃下提取1.5h,第3次加28倍量水,80℃提取2h,每次滤过,合并滤液,减压浓缩,干燥,得到葛根提取物。
本发明提供的一种松苓草颗粒的制备方法,包括以下步骤:
(1)将配方中的人参膏、茯苓提取物、虫草提取物、松花粉提取物、黄精提取物、肉苁蓉提取物、山楂叶提取物、冬瓜皮提取物、银杏叶提取物、月见草提取物、大黄提取物、荷叶提取物、车前子提取物、菊花提取物、番石榴叶提取物、薏苡仁提取物、当归提取物和葛根提取物搅拌混匀;
(2)加入配方量的苹果酸、CMC和木糖醇,搅拌混匀,制颗粒,干燥,即得松苓草颗粒。
实施例3
3.1性状
有中药味,棕色粘稠状。
3.2pH值检查
pH值在7-7.2,可直接食用。
3.3室温稳定性
置于室温不腐败,不变味,不分层。
3.4治疗效果观察
选取45-65岁患有高血脂、高血压、高血糖和高尿酸的四高人群的志愿者100名,将实施例1-2制备的颗粒给志愿者服用,经连续一段时间服用后,患者再去医院检查,表示高血脂、高血压、高血糖、高尿酸及并发症情况明显改善。
Claims (10)
1.一种松苓草颗粒,其特征在于,所述松苓草颗粒含有以下重量份的原料:
2.根据权利要求1所述的松苓草颗粒,其特征在于,所述人参膏的制备方法为:
将购买的人参研磨成粉,加入6-7倍重量的体积分数80%的乙醇加热回流提取3-4次,每次0.8-1.5h;合并滤液,减压干燥,制得人参膏。
所述茯苓提取物的制备方法为:
将茯苓烘干粉碎后,过40-60目筛,加入50-60倍量的水,超声提取25-30min;过滤,得滤液,减压浓缩干燥,制得茯苓提取物。
3.根据权利要求1所述的松苓草颗粒,其特征在于,所述虫草提取物的制备方法为:
将虫草粉碎,加热提取3次,第一次加5-7倍重量的水在65-70℃下提取1.5-2h;第二次加4-6倍量水,68-70℃下提取0.5-1.5h,第3次加3-5倍量水,65-70℃提取0.5-1.5h,每次滤过,合并滤液,滤液减压浓缩,干燥,得到虫草提取物;
所述松花粉提取物的制备方法为:
准确称取松花粉加热回流提取2次,第一次加入15-20重量倍的水,回流提取1-2h;第二次加入10-12倍重量的水,回流提取1-2h,每次滤过,合并滤液,浓缩冷冻干燥,得松花粉提取物。
4.根据权利要求1所述的松苓草颗粒,其特征在于,所述黄精提取物的制备方法为:
将黄精粉碎,过20-40目筛,用石油醚80-90℃回流脱脂后,加热提取3次,第一次加10-18倍重量的水在90-95℃下提取1.5-2h;第二次加10-15倍量水在85-90℃提取0.5-1.5h,第3次加8-12倍量水在85-90℃提取0.5-1.5h,每次滤过,合并滤液,滤液减压浓缩,干燥,得到黄精提取物;
所述肉苁蓉提取物的制备方法为:
将肉苁蓉粉碎,加热提取3次,第一次加10-12倍重量的水在80-85℃下提取1.5-2h;第二次加8-10倍量水在85-90℃提取0.5-1.5h,第3次加6-8倍量水在85-90℃提取0.5-1h,每次滤过,合并滤液,滤液减压浓缩,干燥,得到肉苁蓉提取物。
5.根据权利要求1所述的松苓草颗粒,其特征在于,所述山楂叶提取物的制备方法:
称取山楂叶,加入15-20倍量的蒸馏水、0.2-0.4%的纤维素酶和0.2-0.4%的果胶酶,用盐酸调pH值到4-5,在45-55℃恒温振荡酶解100-150min,先对山楂叶细胞壁进行破坏,然后升温到85-90℃下浸提60-90min;待冷却至室温后,离心分离,得上清液;剩余山楂叶残渣用80-90℃水洗涤1次,离心分离,得洗涤液;将2次上清液合并,滤液减压浓缩,干燥,得到山楂叶提取物;
所述冬瓜皮提取物的制备方法为:
将冬瓜皮用8-10倍乙醇回流提取3-4次,每次提取1-2h;残渣挥发去掉乙醇后,加入残渣8-10倍重量的水提取2-3次,每次提取1-2h;过滤后,滤液减压浓缩,干燥,即得冬瓜皮提取物。
6.根据权利要求1所述的松苓草颗粒,其特征在于,所述银杏提取物的制备方法为:
将干银杏粉碎过40-60目筛,用乙醇超声提取2次,第一次加入10-20倍的体积分数90%的乙醇,在70℃下400W功率下提取1-2h;第二次在10-15倍的体积分数75%的乙醇,在60-70℃下300W功率下提取1-2h,合并滤液,减压浓缩、干燥,得到银杏提取物;
所述月见草提取物的制备方法为:
月见草粉碎过40-60目筛,用25-30倍重量的体积分数80%的乙醇加热80-90℃,回流提取2次,每次合并滤液,浓缩后,再加入3-4倍体积量的体积分数95%的乙醇除杂,离心后,得滤液,滤液浓缩得月见草提取物。
7.根据权利要求1所述的松苓草颗粒,其特征在于,所述银杏提取物的制备方法为:
将大黄粉碎,加热提取2次,第一次加8-11倍量水在70-90℃提取0.5-2h,第二次加6-8倍量水在85-95℃提取0.5-1h,每次滤过,合并滤液,滤液减压浓缩,干燥,得到大黄提取物;
所述荷叶提取物的制备方法为:
将荷叶烘干、粉碎,过100-160目筛,加入体积浓度60%的乙醇,浸泡10-12h,浸泡后的荷叶粉末用40-45倍重量的体积浓度75%的乙醇超声提取20-25min,滤液浓缩干燥,得到荷叶提取物;
所述菊花提取物的制备方法为:
称取菊花适量,回流提取两次,第一次加6-15倍量水,浸泡超声0.5-1h,提取0.5-2h,过滤,第二次加6-15倍量水,提取0.5-2h,过滤,两次滤液合并,滤液减压浓缩,干燥,即得菊花提取物。
8.根据权利要求1所述的松苓草颗粒,其特征在于,所述大黄提取物的制备方法为:
所述车前子提取物的制备方法为:
将车前子粉碎,加热提取3次,第一次加25-30重量倍的水在80-95℃下提取1.5-2h;第二次加15-25倍量水,80-90℃下提取0.5-1.5h,第3次加25-28倍量水,80-90℃提取0.5-2h,每次滤过,合并滤液,滤液减压浓缩,干燥,得到车前子提取物;
称取番石榴叶适量,加热提取两次,第一次加5-10倍量水,加热煎煮至80-90℃,提取0.5-2h,过滤,第二次加6-8倍量水,加热至85-90℃,提取0.5-2h,过滤,两次滤液合并,滤液减压浓缩,干燥,即得石榴叶提取物;
所述薏苡仁提取物的制备方法为:
称取薏苡仁适量,粉碎,加热提取两次,第一次加5-7倍量水,加热煎煮至70-90℃,提取0.5-2h,过滤,第二次加6-8倍量水,加热至85-90℃,提取1-2h,过滤,两次滤液合并,滤液减压浓缩,干燥,即得薏苡仁提取物。
9.根据权利要求1所述的松苓草颗粒,其特征在于,所述番石榴叶提取物的制备方法为:
所述当归提取物的制备方法为:
当归粉碎后,于12-15倍重量的体积分数70%的乙醇溶液中浸泡10-12h后,回流提取1-3h,滤液减压浓缩,干燥,即得当归提取物;
所述葛根提取物的制备方法为:
将葛根粉碎,加热提取3次,第一次加25-30重量倍的水在80-95℃下提取1.5-2h;第二次加15-25倍量水,80-90℃下提取0.5-1.5h,第3次加25-28倍量水,80-90℃提取0.5-2h,每次滤过,合并滤液,减压浓缩,干燥,得到葛根提取物。
10.一种权利要求1-9任一项所述的松苓草颗粒的制备方法,包括以下步骤:
(1)将配方中的人参膏、茯苓提取物、虫草提取物、松花粉提取物、黄精提取物、肉苁蓉提取物、山楂叶提取物、冬瓜皮提取物、银杏叶提取物、月见草提取物、大黄提取物、荷叶提取物、车前子提取物、菊花提取物、番石榴叶提取物、薏苡仁提取物、当归提取物和葛根提取物搅拌混匀;
(2)加入配方量的苹果酸、CMC和木糖醇,搅拌混匀,制颗粒,干燥,即得松苓草颗粒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610563078.3A CN106110055A (zh) | 2016-07-15 | 2016-07-15 | 一种松苓草颗粒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610563078.3A CN106110055A (zh) | 2016-07-15 | 2016-07-15 | 一种松苓草颗粒及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106110055A true CN106110055A (zh) | 2016-11-16 |
Family
ID=57283574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610563078.3A Withdrawn CN106110055A (zh) | 2016-07-15 | 2016-07-15 | 一种松苓草颗粒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106110055A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108813343A (zh) * | 2018-06-14 | 2018-11-16 | 广东日可威富硒食品有限公司 | 一种苦瓜营养保健面条及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103006769A (zh) * | 2013-01-05 | 2013-04-03 | 山东沃华医药科技股份有限公司 | 一种治疗心脑血管疾病的中药组合物及其制备方法 |
CN103705594A (zh) * | 2013-12-12 | 2014-04-09 | 南昌济顺制药有限公司 | 治疗高脂血症的中药组合物及其制备方法 |
CN105362448A (zh) * | 2015-12-11 | 2016-03-02 | 杨石 | 一种保健食品组合物和用途及其制备方法 |
-
2016
- 2016-07-15 CN CN201610563078.3A patent/CN106110055A/zh not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103006769A (zh) * | 2013-01-05 | 2013-04-03 | 山东沃华医药科技股份有限公司 | 一种治疗心脑血管疾病的中药组合物及其制备方法 |
CN103705594A (zh) * | 2013-12-12 | 2014-04-09 | 南昌济顺制药有限公司 | 治疗高脂血症的中药组合物及其制备方法 |
CN105362448A (zh) * | 2015-12-11 | 2016-03-02 | 杨石 | 一种保健食品组合物和用途及其制备方法 |
Non-Patent Citations (2)
Title |
---|
陈君慧: "《中华酒典》", 31 January 2013, 黑龙江科学技术出版社 * |
韦桂宁: "《图解中医六大名著》", 31 May 2014, 中医古籍出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108813343A (zh) * | 2018-06-14 | 2018-11-16 | 广东日可威富硒食品有限公司 | 一种苦瓜营养保健面条及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101912484B (zh) | 一种治疗高血压、高血脂及高血糖的中药组合物 | |
CN1170588A (zh) | 一种纯天然植物人体生命核能营养基质 | |
CN102784295B (zh) | 一种改善女性更年期综合症的保健制剂配方及其制备方法 | |
CN1569207A (zh) | 乌发延寿方剂及其制备方法 | |
CN101485830A (zh) | 一种纯中药抗衰老保健胶囊 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
CN105166950A (zh) | 一种香仙鲜保健兔肉及其制备方法 | |
CN103734835B (zh) | 一种山药活性功能饮料及其制备方法 | |
CN106138869A (zh) | 一种治疗四高的中药组合物及其制备方法 | |
CN107853517B (zh) | 一种提神抗疲劳的中药饮料及其制备方法 | |
CN103301413A (zh) | 一种治疗高血脂合并高血糖症的中药组合物 | |
KR20120056425A (ko) | 탈모에 효과적인 건강보조식품 및 그 제조방법 | |
CN112933203A (zh) | 一种抗疲劳改善性功能药酒的中药组合物及其制备方法 | |
CN101518595A (zh) | 具有降脂减肥、抗氧化功能的药物组合物及其制备方法 | |
CN105998661A (zh) | 一种中药组合物及其制备方法 | |
CN107692220A (zh) | 增强人体免疫力的保健药膳食品及制备方法 | |
CN107333926A (zh) | 一种沙棘保健茶及其制备工艺 | |
CN104524146A (zh) | 一种预防和辅助治疗“三高症”中药组合物及其应用 | |
CN103960429A (zh) | 一种具有健康减肥作用的保健食品 | |
CN109315666A (zh) | 用于肾病的食疗营养素固体饮料及其制备方法 | |
CN105708762B (zh) | 一种决明子降脂牙膏 | |
CN101700341A (zh) | 一种养肾护肝、排毒养颜生物组合物及其口服液的制备方法 | |
KR20160000695A (ko) | Dha 함유 기억력 강화 및 피로회복 증진용 한약재 조성물 수능환 및 그 제조방법 | |
KR101783549B1 (ko) | Dha 함유 피로회복 증진 보조식품용 조성물 수능단(수능원) 및 그 제조방법 | |
CN103725587A (zh) | 黄精山楂醋及其生产方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161116 |
|
WW01 | Invention patent application withdrawn after publication |